MichaelJRamirezMD

Oncology • Philadelphia, PA

Instructor, Medical Oncology, Jefferson Medical College-Thos Jefferson Univ

Join to view full profile

Dr. Ramirez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ramirez's full profile

Already have an account?

Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107
Phone+1 215-955-8874

Fax+1 215-955-2340

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1995 - 1998
Temple University HospitalResidency, Internal Medicine, 1991 - 1994
Lewis Katz School of Medicine at Temple UniversityClass of 1991

Certifications & Licensure

PA State Medical License 1993 - 2026
DE State Medical License 2018 - 2025
NJ State Medical License 2018 - 2025
NC State Medical License 1995 - 1998
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013

Clinical Trials

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2009 Feb 05
Completed
Phase 2
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Start of enrollment: 2011 May 25
Active, not recruiting
Phase 2
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
Completed
Phase 1, Phase 2
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
Completed
Phase 2
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2013 Apr 25
Completed
Phase 2
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Jonathan Pan, Sushil Ghimire, S. Onder Alpdogan, Andrew E. Chapman, Matthew Carabasi
Leukemia & Lymphoma. 2021-02-23
72 citations
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Gregory J. Kubicek, Maria Werner-Wasik, Mitchell Machtay, Gayle Mallon, Thomas J. Myers
International Journal of Radiation Oncology, Biology, Physics. 2009-06-01
78 citations
Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy
Lyndsay Harris, Vlayka Liotcheva, Gloria Broadwater, Michael J. Ramirez, Peter Maimonis
Journal of Clinical Oncology. 2001-03-15